LinkedIn Image Downloadable Slides From Integrating New Treatments for HER2+ Early Breast Cancer: Time for a Risk-Adapted Approach

Downloadable Slides From Integrating New Treatments for HER2+ Early Breast Cancer: Time for a Risk-Adapted Approach

View Activity

Activity Features

Downloadable Slides

Learning Objectives

After successful completion of this educational activity, participants should be able to:

  • Evaluate the results of recent clinical trials in HER2+ early breast cancer that explore the evolution of adjuvant treatment strategies
  • Select the optimum HER2-targeted strategy and duration of treatment to improve long-term disease endpoints in patients with HER2+ early breast cancer
  • Identify supportive care interventions to minimize adverse events with HER2-targeted therapy
  • Understand the limitations of health care funding for HER2+ early breast cancer and the need for a risk-adapted strategy

Activity Overview

Enhance your understanding of optimal treatment approaches for HER2+ early breast cancer with these prIME Oncology downloadable slides. A variety of therapeutic strategies are covered, including short duration regimens, extended adjuvant therapy, dual HER2 blockade, and patient selection for these strategies. Optimizing the risk-benefit profile of different regimens is also addressed, with information on prevention and management of adverse events. Finally, emerging agents and potential future opportunities provided by new HER2-targeted strategies that address areas of continuing unmet clinical need are covered.

Provider

This activity is provided by prIME Oncology.

Support

This educational activity is supported by a grant from Puma Biotechnology.

Featured Expert

  • Sibylle Loibl, MD, PhD, German Breast Group, Neu-Isenburg, Centre for Haematology and Oncology Bethanien, Frankfurt, Germany

Featured Topic

The case for dual blockade

Featured Expert

  • Michael Untch, MD, PhD, HELIOS Klinikum Berlin-Buch, Berlin, Germany

Featured Topic

The case for extended adjuvant treatment

Featured Expert

  • Thomas Bachelot, MD, PhD, Centre Léon Bérard, Lyon, France

Featured Topic

The case for reduced treatment

Featured Expert

  • Wolfgang Janni, MD, PhD, University of Ulm, Ulm, Germany

Featured Topic

Optimizing the risks and benefits of treatment

Featured Expert

  • Suzette Delaloge, MD, MSc, Gustave Roussy, Villejuif, France

Featured Topic

Borrowing from Maria to treat Sophia: A risk-adapted approach to treatment

Featured Expert

  • Cristina Saura, MD, PhD, Vall d’Hebron University Hospital, Barcelona, Spain

Featured Topic

Emerging treatments for HER2+ and mutant breast cancer

Featured Expert

  • Hope S. Rugo, MD, FACP, University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States

Featured Topic

prIME Points™